Molly Bowen

CRS:

BJMC

Role:

Communications

Position:

Communications Associate

Email:

molly.bowen@jhmi.edu

Phone:

410-955-9948

Molly Bowen is Communications Associate at the Johns Hopkins Center for Clinical Global Health Education (CCGHE). She establishes and maintains systems for information management, and devises strategies, develops content, and manages production and workflow for organizational reporting, donor relations, media outreach, marketing and promotional materials, and the CCGHE website. She also is charged with communications for the Baltimore-Washington-India Clinical Trials Unit.

Prior to joining CCGHE in March 2015, Molly worked for more than 15 years with Dr. D.A. Henderson, first joining the Johns Hopkins Center for Civilian Biodefense Studies in 1999, and moving with the group in 2003 to found the UPMC Center for Health Security. As the first non-faculty member hired, Molly established administrative, finance, and communications functions for the organization, and served for 10 years as Senior Communications Specialist. Prior to that position, she worked for 9 years with ORBIS Associates, non-profit American Indian owned and managed educational consulting firm in Washington, DC.

She has a BA in American Studies from Keene State College, Keene, New Hampshire.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More